About Neurive
Neurive is a company based in Gimhae (South Korea) founded in 2018 by Jae Jun Song. Neurive has raised $1.01 million across 2 funding rounds from investors including MAGNA Investment, SL Investment and XL Biotec. Neurive operates in a competitive market with competitors including ONWARD, Nalu Medical, Atlantic Therapeutics, Synchron and Neuronoff, among others.
- Headquarter Gimhae, South Korea
- Founders Jae Jun Song
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.01 M (USD)
in 2 rounds
-
Latest Funding Round
$846.58 K (USD), Seed
Sep 26, 2021
-
Investors
MAGNA Investment
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neurive
Neurive has successfully raised a total of $1.01M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $846.58 thousand completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neurive
Neurive has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include MAGNA Investment, SL Investment and XL Biotec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A multi-asset investment firm based in Abu Dhabi, UAE, is operated.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
XL Biotec is engaged in supplying biotechnology research products.
|
Locked | Locked | Locked |
Investor details for Neurive
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neurive
Investment portfolio details for Neurive
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neurive
Detailed financials for Neurive
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurive Comparisons
Peer comparison for Neurive
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neurive
Neurive operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ONWARD, Nalu Medical, Atlantic Therapeutics, Synchron and Neuronoff, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for spinal cord injuries are developed and delivered.
|
|
| Locked | Locked | Locked |
Developer of a neurostimulation system for managing intractable chronic pain
|
|
| Locked | Locked | Locked |
Non-invasive wearable devices for pelvic floor strengthening are developed.
|
|
| Locked | Locked | Locked |
Implantable bioelectronics are developed for neurological condition treatments.
|
|
| Locked | Locked | Locked |
Neuromodulation devices are developed to restore and improve organ activity.
|
|
| Locked | Locked | Locked |
Neuromodulation devices for neurological disorders are developed and offered.
|
Detailed competitors of Neurive
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurive
Complete news archive for Neurive
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurive
Neurive was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Neurive is headquartered in Gimhae, South Korea. It is registered at Gimhae, Gyeongsangnam-do, South Korea.
Jae Jun Song is the current CEO of Neurive. They have also founded this company.
Neurive is a funded company, having raised a total of $1.01M across 2 funding rounds to date.
Neurive was founded in 2018 as a developer of electronic and digital medicines targeting neurological disorders. Therapeutic devices are provided that employ neuromodulation techniques and AI-driven vagus nerve stimulation. Conditions addressed include tinnitus, depression, anxiety, insomnia, and cognitive dysfunction associated with degenerative brain diseases. Operations focus on innovative treatments within the healthcare technology sector.
Neurive's top competitors include ONWARD, Synchron and Nalu Medical.
Neurive has 4 investors. Key investors include MAGNA Investment, SL Investment, XL Biotec, and Incheon Catholic University.